ClinConnect ClinConnect Logo
Search / Trial NCT05807958

Allergy Testing of Soldiers Prepared for International Mission

Launched by QUEEN ASTRID MILITARY HOSPITAL · Mar 28, 2023

Trial Information

Current as of July 26, 2025

Completed

Keywords

ClinConnect Summary

This clinical trial is studying allergy testing in adult military personnel who are preparing for international missions. The goal is to find out which allergen extracts are most relevant for soldiers, helping them understand potential allergic reactions they might face in different regions. Participants will take part in a skin prick test, where small amounts of 22 allergens will be applied to their skin to see if they react to any of them.

To be eligible for this study, participants must be adult military personnel aged 18 to 65 years, and they can include soldiers who have and haven't been exposed to allergens before. Those who are doing desk jobs and are not going on international missions will serve as a comparison group. However, individuals with certain skin conditions, those taking specific medications, or pregnant women cannot participate due to safety concerns. If you join this trial, you can expect to undergo a simple skin test, and your participation could help improve allergy management for military personnel in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult military personnel (18-65y) will be included. Soldiers with and without previous exposure to allergens in the regions of interest will be included. Soldiers who are performing desk tasks and not selected for international missions will serve as controls.
  • Exclusion Criteria:
  • Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment
  • Use of antihistaminic medication \< 7 days before the start of the study
  • Use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study
  • Use of topical corticoids on the forearm \< 7 days before the start of the study
  • Use of Omalizumab \< 6 months before the start of the study
  • Pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery).

About Queen Astrid Military Hospital

Queen Astrid Military Hospital is a leading clinical research institution dedicated to advancing medical knowledge and improving patient care through rigorous clinical trials. With a commitment to excellence in military and civilian health, the hospital leverages its state-of-the-art facilities and highly skilled medical professionals to conduct innovative research across various therapeutic areas. By collaborating with academic institutions and industry partners, Queen Astrid Military Hospital aims to enhance treatment options and contribute to the global medical community while ensuring the safety and well-being of participants in all studies.

Locations

Brussels, , Belgium

Patients applied

0 patients applied

Trial Officials

Ilan Baron, MD

Principal Investigator

Military Hospital Queen Astrid

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials